On December 11, 2025, Eli Lilly dropped a press release that quietly rewired the entire obesity drug industry.
Their newest weight loss drug, retatrutide, finished its first late-stage clinical trial. The headline number: people on the highest dose lost an average of 71 pounds — about 28.7% of their body weight — in 68 weeks.
For comparison:
- Ozempic (semaglutide): about 33 pounds, or 14.9% of body weight, in 68 weeks
- Zepbound (tirzepatide): about 50 pounds, or 22.5% of body weight, in 72 weeks
- Retatrutide: 71 pounds, 28.7%, in 68 weeks
These aren’t small differences. Retatrutide is in a different league. (For the deep dive on why each new generation of weight loss drug outperforms the last, see our breakdown of Ozempic vs Mounjaro and the receptor-by-receptor story.) And this is just the first of eight late-stage trials Lilly is running on this drug — seven more results are expected throughout 2026.
Here’s what’s going on, in plain English.
What retatrutide actually is
Retatrutide is a once-weekly injection. You take it Sunday night, you don’t think about it again until next Sunday. Same delivery as Ozempic and Zepbound.
The difference is what’s in it. Ozempic activates one biological switch (called GLP-1) that makes you feel less hungry and slows down how fast food leaves your stomach. Zepbound activates two switches at once (GLP-1 and GIP) — and the second switch makes the first one work better. Retatrutide hits three switches: the same two as Zepbound, plus a third one called glucagon.
Here’s the weird thing about that third switch: glucagon, on its own, would actually raise your blood sugar (not what you want for a weight loss drug). But when you fire it at the same time as the other two, it does something different — it makes your body burn more energy at rest, like turning up the dial on your metabolism a notch.
Translation: retatrutide doesn’t just suppress your appetite harder than its predecessors. It also makes you burn more calories without doing anything different.
The TRIUMPH-4 trial results
The first of Lilly’s eight late-stage trials was called TRIUMPH-4. It studied adults who had both obesity AND knee arthritis — a tough population because they often can’t exercise much, which makes weight loss especially hard.
Both endpoints the trial was measuring hit hard:
- Weight loss: 28.7% average reduction at 68 weeks (12 mg dose)
- Knee pain: 75.8% reduction in pain scores
- Pain-free: More than 1 in 8 patients on the drug were COMPLETELY free of knee pain at trial end
- Other improvements: Cardiovascular risk markers and blood pressure dropped noticeably
For a population that struggles with both weight and chronic pain, this is a big deal.
Retatrutide side effects (because there’s always a catch)
Not everything was perfect. The trial revealed a side effect that no one was expecting from earlier studies: dysesthesia, which is medical-speak for weird tingling, burning, or numbness sensations in the skin.
Rates by group:
- Placebo: 0.7% of patients
- Retatrutide 9 mg: 8.8%
- Retatrutide 12 mg: 20.9%
That 12 mg rate is high enough that it’ll almost certainly show up on the FDA label if and when this drug gets approved.
People also dropped out of the trial at higher rates than placebo — 12.2% on the 9 mg dose, 18.2% on the 12 mg dose, vs 4% on placebo. Lilly mentioned that some of those dropouts happened because patients lost more weight than they wanted to. That’s not a problem most weight loss drugs run into.
What’s coming next from the TRIUMPH program
Lilly has seven more late-stage trials expected to finish through 2026. The two most important:
- TRIUMPH-1: General obesity (no diabetes), 80 weeks. This is the trial that will be the basis of the FDA approval submission. Expected mid-to-late 2026.
- TRIUMPH-2: Obesity in people with type 2 diabetes, 80 weeks. Also expected mid-to-late 2026.
If those two reproduce TRIUMPH-4’s effectiveness without making the dysesthesia issue worse, retatrutide is probably looking at FDA submission late 2026 or early 2027 — meaning approval potentially by mid-2028.
Retatrutide isn’t the only next-generation weight loss drug in the FDA pipeline. Novo Nordisk filed for approval of its own combination drug, CagriSema, in late 2025 — our breakdown of CagriSema and how it stacks up against retatrutide is here.
What this means for everything else
Three takeaways, big picture:
- Ozempic was the start of a curve, not the peak. When semaglutide first launched, the assumption was that 14–15% weight loss was the ceiling. Tirzepatide pushed it to 22–23%. Retatrutide is now at 28–29%. We don’t know where this curve actually ends.
- Bariatric surgery comparison is real now. Surgical weight loss procedures typically deliver 25–35% body weight reduction long-term. Retatrutide’s 28.7% gets you in that range — without surgery. That changes the math for an enormous number of people.
- There’s always a tradeoff. Bigger results come with bigger side effects. The dysesthesia rate, and the dropout rate, are higher than anything we’ve seen before. The next trials need to find the sweet spot between effectiveness and tolerability.
For research labs working with these compounds, the practical implication is straightforward: the pipeline is getting wider, faster, and more competitive every quarter. Retatrutide’s success makes the next wave of compounds (with four or even five receptor targets) significantly more fundable.
We’ll update this article when TRIUMPH-1 reads out later this year.
Strictly for qualified research use only. Nothing in this article should be construed as medical advice or as a recommendation for any therapeutic protocol.
